Generic Name: Ciprofloxacin
Originator’s name: Cipro IV®
Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The bactericidal actions of Ciprofloxacin result from inhibition of the enzymes topoisomerase II (DNA gyrase) and
topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination


Adult Patients:

  • Urinary Tract infection
  • Lower Respiratory tract infection
  • Nosocomial Pneomonia infection
  • Skin and skin stracture infection
  • Bone and joint infection
  • Intra-abdominal infection
  • Acute sinusitis infection
  • Chronic Bacterial Prostatitis infection
  • Empirical Therapy in febrile infection
  • Neutropenic patiens infection
  • Inhalational antrax infection (post

Pediatric patients (1 to 17 years of age):

  • Inhalation Anthrax infection (PostExposure)
  • Infections and Pyelonephritis due to
    Escherichia coli (Patients from 1 to 17
    years of age)
  • Complicated Urinary Tract infection